Synapse Open Synapse
Biology

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Nature Medicine · · 36 min read

In the STOP-V1 and STOP-V2 trials, povorcitinib (an oral JAK1 inhibitor) was superior to placebo in improvement in F-VASI75 score in individuals with nonsegmental vitiligo.

Latest from Nature Medicine